Effective immediately, IXCHIQ® and Ocaliva® have been withdrawn from the market by the U.S. Food and Drug Administration (FDA) due to potential safety concerns.
We're notifying members
Impacted members will receive letters in the mail informing them of the drug changes and encouraging them to discuss concerns or alternative treatment plans with their provider. These changes will only impact a total of 26 members. You can find more information on these changes below.IXCHIQ®
What it treats
IXCHIQ works to prevent chikungunya virus in individuals 18 years and older who are at an increased risk of exposure.Reason for withdrawal
The FDA suspended the biologics license for IXCHIQ due to serious safety concerns, including reports of chikungunya-like illness and hospitalizations following vaccination.Ocaliva®
What it treats
Ocaliva is used to treat biliary cholangitis, a rare liver condition caused by bile build-up.Reason for withdrawal
Ocaliva is being voluntarily withdrawn from the market by the manufacturer, Intercept Pharmaceuticals, at the request of the FDA due to concerns of potential liver damage.